In the SURMOUNT-1 trial, the most common tirzepatide side effects were nausea (24%), diarrhea (17%), constipation (11%), and vomiting (9%) at the 15 mg dose — nearly all gastrointestinal, nearly all mild-to-moderate, and nearly all concentrated during the titration phase when doses were increasing.
This article covers every documented tirzepatide side effect with incidence rates from the SURMOUNT clinical trials, the mechanism behind each one, how long it lasts, what makes it better, and — for the effects that worry users most (hair loss, cancer risk, fatigue) — what the data actually says versus what the internet implies. For dosing, reconstitution, injection, and storage, see the tirzepatide practical guide.
How Common Are Tirzepatide Side Effects? SURMOUNT Trial Numbers
The SURMOUNT clinical trial program (SURMOUNT-1 through SURMOUNT-4) enrolled thousands of participants and provides the most rigorous side-effect data available. Here are the incidence rates at each dose level compared to placebo:
Side Effect | 5 mg | 10 mg | 15 mg | Placebo | Severity |
|---|---|---|---|---|---|
Nausea | 24% | 24% | 24% | 9.5% | Mild-moderate; peaks during titration |
Diarrhea | 12% | 13% | 17% | 7-8% | Mild-moderate; episodic |
Constipation | 6% | 7% | 11% | 3% | Mild-moderate; may persist |
Vomiting | 5% | 6% | 9% | 2% | Mild-moderate; dose-dependent |
Hair loss (alopecia) | 4% | 5% | 6% | ~1% | Mild-moderate; delayed onset |
Injection site reactions | 2% | 3% | 4.5% | -- | Mild; localized |
Acute pancreatitis | 0.2% | 0.2% | 0.2% | 0.2% | Serious; comparable to placebo |
Discontinuation due to AEs | ~4% | ~6% | ~7% | ~3% | -- |
A 2026 Nature Health study analyzing 410,198 Reddit posts across semaglutide and tirzepatide users found substantially higher self-reported rates: 43.5% of 67,008 users reported at least one side effect -- with nausea at 36.9%, fatigue at 16.7%, vomiting at 16.3%, constipation at 15.3%, and diarrhea at 12.6%. The gap between trial data and self-reports reflects either clinical trial underreporting of mild effects or selection bias in who posts about side effects online -- likely both.
The critical context: the vast majority of side effects are gastrointestinal, mild-to-moderate, concentrated during titration, and self-resolving within 2-4 weeks as the body adapts at each dose level. Slow titration -- holding each dose for a full 4 weeks before increasing -- substantially reduces their severity. See the tirzepatide practical guide for the complete titration schedule.
GI Side Effects -- Nausea, Diarrhea, Constipation and Vomiting
GI side effects account for the vast majority of tirzepatide adverse events because the drug's primary mechanism -- delaying gastric emptying and slowing intestinal transit via GLP-1 and GIP receptor activation -- directly affects the digestive system before the appetite and metabolic effects that users are seeking. The GI tract is the drug's first target. These side effects are not incidental -- they are the mechanism at work on the gut before the brain catches up with the appetite suppression signal.
Nausea
The most commonly reported effect at 24% across all dose levels in SURMOUNT-1. Nausea typically peaks within hours of injection, lasts 1-3 days per dose increase, and fades as the body adapts. It recurs briefly with each titration step, which is why slow dose escalation reduces its severity.
Management: eat smaller, more frequent meals. Avoid greasy, fatty, or fried foods -- fat delays gastric emptying independently, amplifying the drug's effect. Ginger tea or ginger chews help many users. Eat slowly and stay upright for at least 30 minutes after meals. Do not skip meals entirely -- an empty stomach can worsen nausea paradoxically.
Diarrhea
Reported at 12-17% (dose-dependent). Episodes typically occur during the first 1-2 weeks at each new dose level and last 1-5 days per episode.
Management: hydration is the priority -- diarrhea plus reduced food intake can cause dehydration quickly, which cascades into fatigue, headaches, and dizziness. A bland diet (rice, bananas, toast, broths) during acute episodes helps. Reduce dietary fat temporarily. If severe or lasting beyond 7 days at the same dose, consult your prescribing physician.
Constipation
Reported at 6-11%. Unlike nausea and diarrhea, constipation can be ongoing rather than titration-limited -- because slowed intestinal motility is a persistent pharmacological effect, not just an adaptation response.
Management: fiber intake of 25-30 g/day (vegetables, whole grains, psyllium husk), adequate water (at minimum 2 L/day), physical activity, and magnesium supplementation if needed. Stool softeners (docusate) for persistent cases.
Vomiting
Reported at 5-9% (dose-dependent). More common with rapid titration (skipping dose levels) and with large, high-fat meals. If vomiting is persistent or severe, it creates a risk of dehydration and electrolyte imbalance -- consult your physician and consider a temporary dose reduction.
Hair Loss -- Why It Happens and Why It's (Usually) Temporary
Tirzepatide causes hair loss in approximately 4-6% of users (vs ~1% placebo) -- but the mechanism is telogen effluvium, a temporary shedding triggered by rapid weight loss, not direct drug toxicity to hair follicles -- meaning the hair loss occurs because the drug works, not because it's harmful, and it's self-resolving in most cases within 6-12 months as weight stabilizes.
What the trials show
Across the SURMOUNT program, alopecia was reported at approximately 4-6% at the highest dose vs ~1% in placebo groups. A 2025 systematic review published in Cureus analyzing 5 studies and 2,905 patients on GLP-1 receptor agonists found a significant gender disparity: women experienced hair shedding at rates up to 7.1%, while men reported it at less than 1%. This mirrors patterns seen with every rapid weight loss intervention -- bariatric surgery, semaglutide, severe caloric restriction -- and reflects hormonal interactions between weight loss, estrogen fluctuations, and the hair growth cycle.
Per the Zepbound product monograph: all hair loss events were rated mild or moderate in severity. No tirzepatide-treated patient discontinued the study due to hair loss.
Why telogen effluvium is not drug toxicity
Telogen effluvium occurs when a metabolic shock -- rapid caloric deficit and fat mobilization -- shifts a larger-than-normal percentage of hair follicles from the anagen (growth) phase to the telogen (resting/shedding) phase. The normal hair cycle has approximately 10-15% of follicles in telogen at any time. A metabolic stress event can push 30%+ of follicles into telogen simultaneously, producing noticeable shedding approximately 2-4 months later (matching the ~3-month telogen phase duration).
This is not the drug damaging hair follicles. It is the rapid weight loss -- which the drug successfully produced -- triggering a normal physiological response. The same shedding occurs after bariatric surgery, crash dieting, major illness, and pregnancy.
Timeline and management
Onset: 2-4 months after starting tirzepatide. Peak shedding: months 3-6. Resolution: self-resolving in most cases within 6-12 months as weight loss slows and the body reaches a new metabolic equilibrium.
What helps: maintain protein intake at 1.0-1.2 g/kg/day (hair is keratin, which requires amino acids to synthesize). Check iron and ferritin levels -- low iron is the most common accelerator of telogen effluvium and is independently correctable. Consider biotin supplementation. Slower titration produces slower weight loss, which reduces the metabolic shock that triggers shedding. For persistent or severe hair loss beyond 12 months, consult a dermatologist.
Fatigue and Tiredness -- The Underreported Effect
Fatigue is the most underreported tirzepatide side effect -- clinical trials didn't flag it as a primary concern, but the 2026 Nature Health study found that 16.7% of semaglutide/tirzepatide users self-reported fatigue, making it the second most commonly mentioned side effect after nausea.
Why tirzepatide makes you tired
The mechanism is likely multifactorial: a significant caloric deficit directly reduces available energy. Metabolic adaptation during weight loss downregulates energy expenditure. Dehydration from GI effects produces fatigue, headaches, and cognitive fog. Nutritional deficiency -- rapid weight loss can deplete iron stores, B12, and electrolytes, all of which contribute to fatigue when levels drop.
Duration and management
Fatigue typically peaks during the first 2-4 weeks at each new dose level and improves as the body adapts. Users who report persistent fatigue throughout their protocol often trace it to inadequate caloric intake, dehydration, or undiagnosed nutrient deficiency.
Management: ensure caloric intake is adequate -- appetite suppression is the goal, but extreme restriction on top of the drug's effect produces unnecessary fatigue. Stay hydrated (minimum 2 L/day). Check B12 and iron levels with bloodwork. Prioritize sleep hygiene.
Does tirzepatide give you energy? Some users report increased energy after the initial adaptation period -- typically after 4-8 weeks on a stable dose. Weight loss reduces systemic inflammation, improves sleep quality (especially in users with sleep apnea), and reduces the metabolic burden of carrying excess weight. Fatigue and increased energy can both be real at different stages of the same protocol.
Cancer Risk, Thyroid Concerns and Pancreatitis
Tirzepatide carries an FDA boxed warning -- the most serious warning category -- for thyroid C-cell tumors observed in rat studies, but clinical trials involving 10,000+ human participants over 72 weeks showed no cancer signal, and the FDA explicitly states that "it is unknown whether ZEPBOUND causes thyroid C-cell tumors in humans."
Thyroid C-cell tumors (boxed warning)
In 2-year rat studies, tirzepatide caused dose-dependent and treatment-duration-dependent increases in thyroid C-cell tumors at clinically relevant plasma exposures. This is a pharmacological effect observed in rodents across the entire GLP-1 receptor agonist class -- semaglutide, liraglutide, and tirzepatide all carry the same boxed warning. It is not unique to tirzepatide.
Human relevance has not been determined. No excess thyroid cancer has been detected in clinical trials with 10,000+ participants. The FDA has ordered a 15-year MTC registry-based study to systematically monitor whether medullary thyroid carcinoma incidence increases following tirzepatide's market introduction. Results are pending -- the question is genuinely open.
Contraindications: personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Pancreatitis
Acute pancreatitis occurred at approximately 0.2% in pooled SURMOUNT data (0.14 per 100 patient-years) -- comparable to the placebo rate. Discontinue immediately if suspected (severe abdominal pain radiating to the back). Do not restart if confirmed.
Gallbladder disease
Cholecystitis and cholelithiasis occurred at 0.6% in diabetes trials and up to 2.5% in weight management trials. The mechanism is rapid fat mobilization increasing cholesterol secretion into bile, promoting gallstone formation -- this occurs with all rapid weight loss methods, not specifically with tirzepatide.
Other Reported Effects -- Headaches, Insomnia, Period Changes and Blood Pressure
Beyond the dominant GI and hair loss effects, tirzepatide users commonly report headaches during early titration, insomnia, and menstrual irregularities -- the last identified as an "unrecognized potential effect" in the 2026 Nature Health study.
Effect | Incidence | Mechanism | Duration | Management |
|---|---|---|---|---|
Headaches | Common during titration | Dehydration + metabolic adaptation | Days; resolves with hydration | Hydrate; OTC pain relief |
Insomnia | Community-reported | GI discomfort, altered meal timing | Variable | Injection timing experimentation |
Menstrual irregularities | Nature 2026 signal | Weight loss reduces adipose estrogen | Variable | Monitor; consult gynecologist |
Blood pressure decrease | Generally beneficial | Weight-loss mediated | Sustained | Monitor for hypotension (1.6%) |
Heart rate increase | Modest; class-wide | GLP-1 receptor activation | Sustained | Monitor; consult if symptomatic |
Injection site reactions | 1.9-4.5% | Local immune response | Days | Rotate sites |
Fertility warning: rapid weight loss can restore ovulation in previously anovulatory women. This is the mechanism behind the "Ozempic babies" phenomenon -- and it applies equally to tirzepatide. Use contraception. Tirzepatide is not recommended during pregnancy (animal studies showed fetal risks).
How Long Do Tirzepatide Side Effects Last?
The majority of tirzepatide side effects follow a predictable pattern: they appear during the first 1-2 weeks at each new dose level, peak during that adaptation window, and fade within 2-4 weeks as the body adjusts -- then recur briefly when the dose increases again, which is why the titration schedule is designed to space increases at minimum 4-week intervals.
Side Effect | Onset | Peak | Resolution |
|---|---|---|---|
Nausea | Hours after injection | Week 1-2 at each new dose | Resolves within 2-4 weeks per dose level |
Diarrhea | Days 1-3 at new dose | Week 1 | Episodes resolve within 1-5 days each |
Constipation | Gradual onset | Ongoing | Managed with fiber/hydration; may persist |
Vomiting | Hours to days | Week 1 at new dose | Resolves 1-2 weeks; recurs with dose increases |
Hair loss | 2-4 months after starting | Months 3-6 | Self-resolves 6-12 months as weight stabilizes |
Fatigue | Week 1 at each dose | Week 2-4 | Improves as body adapts |
Headaches | First days at new dose | Week 1 | Resolves within days; hydration-dependent |
The key pattern: GI effects are titration-related and self-resolving. Hair loss is delayed and self-resolving on a longer timeline. Fatigue is adaptation-related and improves with metabolic adjustment. Slow titration compresses the severity of each episode. The tirzepatide calculator can help ensure dose accuracy at each level.
Frequently Asked Questions
Does tirzepatide cause cancer?
Tirzepatide carries an FDA boxed warning based on thyroid C-cell tumors found in rat studies -- but no cancer signal has been detected in human clinical trials involving 10,000+ participants over 72 weeks. The FDA explicitly states the human relevance is unknown and has ordered a 15-year monitoring study. This is a class-wide warning that applies to all GLP-1 receptor agonists, not a tirzepatide-specific concern. Contraindicated in patients with personal/family history of MTC or MEN 2 syndrome.
Why am I gaining weight on tirzepatide?
Three common causes: (1) still at a sub-therapeutic dose during early titration -- 2.5 mg produces minimal weight loss for many users; (2) water retention fluctuations masking fat loss -- measure waist circumference, not just scale weight; (3) caloric intake still exceeding expenditure despite reduced appetite. For users on compounded tirzepatide, verify product purity through independent lab testing -- underdosed vials produce sub-therapeutic dosing. See how to verify peptide quality for the full process.
How to prevent hair loss on tirzepatide?
You cannot fully prevent telogen effluvium triggered by rapid weight loss, but you can reduce its severity: maintain high protein intake (1.0-1.2 g/kg/day), check iron and ferritin levels, consider biotin supplementation, and titrate slowly. Hair regrows when weight stabilizes -- most cases resolve within 6-12 months. Consult a dermatologist if shedding is severe or persistent.
Does tirzepatide affect fertility or periods?
The 2026 Nature Health study identified menstrual irregularities as "unrecognized potential effects." Rapid weight loss reduces estrogen stored in adipose tissue, altering hormone ratios. Importantly, weight loss can restore ovulation in previously anovulatory women -- meaning tirzepatide can increase fertility when the user's assumption is the opposite. Use contraception. Tirzepatide is not recommended during pregnancy (FDA Pregnancy Category X for weight loss indication).
This article is for educational and informational purposes only and does not constitute medical advice. Tirzepatide (Zepbound, Mounjaro) is an FDA-approved prescription medication with a boxed warning for thyroid C-cell tumors in rats. Side-effect incidence rates are from published clinical trial data (SURMOUNT program) and FDA prescribing information. Always consult a qualified healthcare provider before starting, stopping, or adjusting any medication. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
